Amnovis celebrates 5 Years of Innovation with 100,000 3D-Printed Implants Shipped

• Milestone Achieved: Promethean Restorative’s FDA-Approved SI Fixation Implant Marks Amnovis’ 100,000th Implant Delivery   
• Scaling Up: Amnovis to Ship 50,000+ Parts in 2025, Driven by Demand for 3D-Printed Titanium Implants
• Driving Innovation: Amnovis Transforms Emerging 3D Printing Technologies, Materials and Applications into Scalable Manufacturing Solutions Like Heat Treatment–Free Titanium 

Aarschot, Belgium - October 14, 2025

Amnovis, a contract manufacturer specializing in 3D-printed medical devices and high-performance applications, proudly marks its fifth anniversary with the shipment of its 100,000th 3D-printed implant. Founded in June 2020 by Peter Mercelis and Ruben Wauthle, Amnovis was built on a clear mission: to deliver high-quality products, exceptional customer service, and reliable on-time delivery to demanding and regulated industries. 

"From day one, we wanted Amnovis to be more than just another supplier," said Ruben Wauthle, CEO and Co-founder of Amnovis. "We set out to build a company that consistently delivers high-quality parts, communicates transparently, and meets deadlines. Five years later, we’re proud to say we’re doing exactly that." 

With a customer acceptance rate exceeding 99.9% and an on-time delivery rate above 90% for three consecutive years, Amnovis has become a trusted partner in the medical device industry. The milestone 100,000th implant was Promethean Restorative’s FDA-approved SI fixation device, manufactured and delivered by Amnovis to support their product launch.  

Their successful launch was supported by Amnovis’s structured approach and regulatory expertise, including the use of its FDA Master File to streamline FDA approval. Glenn Bowman, President & CEO of Promethean Restorative, confirmed the impact: “It accelerated our go-to-market timeline and reduced regulatory friction. Their clarity in documentation and speed in execution helped us avoid delays and maintain momentum.” 

Amnovis is growing on the foundation of these performance metrics. In 2025 alone, the company expects to ship over 50,000 implants, half of its five-year total in just one year, illustrating its rapid scale-up. To meet this demand, Amnovis is actively expanding its production capacity for medical devices and other high-performance applications, including aerospace, the semiconductor industry, and advanced engineering components. 

"Innovation is in our DNA," Wauthle added. "We don’t just follow trends. We redefine the state-of-the-art in 3D printing by bridging the gap between emerging technologies and scalable, real-world applications. That’s what sets Amnovis apart." 

Over the past five years, Amnovis has developed and validated several innovations, some of which have already been transferred into production, while others are progressing through pilot and R&D phases: 

• Heat Treatment–Free Titanium: Amnovis is the only contract manufacturer to offer 3D-printed pure titanium that meets ASTM standards without requiring heat treatment. This validated material is now a workhorse in spine, CMF, and orthopedic applications. 

• Deformable Implants: A patented concept enabling patient-specific implants by deforming highly porous regions of standardized components. This innovation offers customization at the cost of standard manufacturing and is being co-developed with customers for market entry.  

• CuperNova: An IP protected powder modification method that enhances the laser absorptivity of copper alloys, improving shelf life and flowability while enabling printing with standard lasers. Amnovis is scaling both powder modification and pilot manufacturing lines for industrial applications. 

• Multi-Metal 3D printing: Currently in R&D, Amnovis is developing capabilities to print components using two or more metals via L-PBF, a promising step toward next-generation applications. 

"As we look ahead, we’re excited about the opportunities to scale our impact even further," Wauthle concluded. "We’re building on a solid foundation of quality and reliability, and we’re committed to turning cutting-edge ideas into real-world solutions for our customers." 

ABOUT AMNOVIS

Amnovis is an independent, innovation-driven additive manufacturing company specializing in high-end 3D-printed products for regulated and high-tech industries, with a strong focus on medical devices. Leveraging deep process and material expertise, Amnovis delivers state-of-the-art solutions, from patient-specific implants to scalable volume production. With a fully digital, ISO 13485:2016-certified workflow, Amnovis partners with OEMs worldwide to accelerate product development, streamline validation, and raise the bar in additive manufacturing. By bridging emerging technologies with real-world applications, Amnovis continuously redefines the possibilities of 3D printing. 

For more information, visit www.amnovis.com or follow Amnovis on LinkedIn.

MEDIA CONTACT

Ruben Wauthle, CEO & Co-founder  -  ruben.wauthle@amnovis.com  -  +32 498 302894

MEDIA PACKAGE

Media package with pictures optimized for online use can be downloaded from the link below. For high resolution pictures, please contact us.

Amnovis logo to be used for white backgrounds:

Amnovis logo to be used for other backgrounds: 

Amnovis PR-251008 Figure 1. Scaled replica of Amnovis’ 100,000th shipped implant (product courtesy of Promethean Restorative LLC):

Amnovis PR-251008 Figure 2. Scaled replica of Amnovis’ 100,000th shipped implant displayed in front of standard SI fixation implants (product courtesy of Promethean Restorative LLC):

Amnovis PR-251008 Figures 3-4. Selected L-PBF metal 3D printers installed at Amnovis:

Amnovis PR-251008 Figure 5-6. SI fixation implants (product courtesy: Promethean Restorative LLC):